Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

Jayanta Paul

Abstract

Background: Number of non-alcoholic fatty liver disease (NAFLD) cases is increasing over time due to alteration of food habit, increase incidence of metabolic syndrome, and lack of exercise. Liver biopsy is the test for diagnosis and staging of NAFLD, but nowadays several biochemical markers, scoring systems, and imaging studies are available to diagnose and stage NAFLD which is linked to end-stage liver disease, hepatocellular cancer, and elevated cardiovascular- and cancer-related morbidity and mortality. Therefore urgent diagnosis and management are required to avoid complications related to NAFLD. This review summarizes recent advances in diagnosis and medical management of non-alcoholic fatty liver disease.

Main text: Recently published studies from PubMed, Red Cross, Copernicus, and also various previous studies were reviewed. We have discussed various non-invasive methods for detection of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), and hepatic fibrosis. Non pharmacological therapies for NAFLD, indications, and approved medications for NAFLD and other commonly used non-approved medications have been discussed in this review article.

Conclusions: Multiple non-invasive tests are available for diagnosis of NAFLD, and its different stages however gold standard test is liver biopsy. NALFD without NASH and significant fibrosis is treated by lifestyle modifications which include moderate to vigorous exercise and diet modification. To improve hepatic steatosis, minimum of 3–5% of body weight loss is necessary, but > 7–10% weight reductions is required for histological improvement in NASH and fibrosis. Pharmacotherapy is indicated when patient is having NASH with significant fibrosis.

Keywords: NAFLD, NASH, Hepatic fibrosis, Recent advances in NAFLD, Non-invasive diagnosis of NAFLD, Medical management of NAFLD

Background

Incidence and prevalence of “Non-alcoholic fatty liver disease” (NAFLD) is increasing over time mainly due to bad food habit, weight gain, and sedentary lifestyle. NAFLD is the most common cause of abnormal liver function tests (LFTs) in the UK [1]. In the USA, prevalence of NAFLD is in between 10 and 30%, which is similar to Asia and Europe [2, 3]. Singh et al. in 2004 [4] showed that 24.5% of healthy attendants had evidence of fatty liver on abdominal ultrasound. NAFLD is commonly associated with one or more component of metabolic syndrome such as obesity, diabetes mellitus, and dyslipidemia and is defined as the presence of ≥ 5% hepatic steatosis in histological examination without evidence of hepatocellular injury such as hepatocyte ballooning [5]. Around 20% of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) which may progress to cirrhosis [6], however most common cause of death in NAFLD patients is cardiovascular disease,
and NAFLD is the third most common cause of hepatocellular carcinoma [5]. “Burned out” NAFLD can be a hidden cause of cryptogenic cirrhosis. So, early diagnosis, and treatment of NAFLD and underlying predisposing factors are important to avoid liver damage which may progress to liver failure.

**Diagnosis**

Liver biopsy is the gold standard test for diagnosis, grading, and histological assessment of NAFLD, and a four-point histopathologic grading system is used to assess severity of steatosis that ranges from 0 to 3, depending on presence of the percentage of fat-containing hepatocytes (Table 1) [7]. But the value of a liver biopsy for the diagnosis of NAFLD in routine clinical practice is controversial, especially in the presence of a generally good prognosis for most patients with NAFLD, the lack of an established form of effective therapy, and the risks and costs associated with the liver biopsy.

Before considering the diagnosis of NAFLD, alcoholic fatty liver has to be excluded. Significant alcohol intake is considered when alcohol consumption > 7 standard drinks/week (70 g ethanol) in women and > 14 (140 g ethanol) in men (according to Asia-Pacific Guidelines) or > 21 standard drink on average per week in men and > 14 standard drink per week in women (according to AASLD guidelines) or > 30 g/day in men and > 20 g/day in women (according to EASL guideline). One standard drink in Asian specific area and Europe is roughly 10 gms per day (according to EASL guideline). One standard drink in Asia specific area and Europe is roughly 10 gms per day (according to Asia-Pacific Guidelines) or > 21 standard drink per week in women (according to EASL guideline). One standard drink in Asia specific area and Europe is roughly 10 gms per day (according to Asia-Pacific Guidelines) or > 21 standard drink per week in women (according to EASL guideline). One standard drink in Asia specific area and Europe is roughly 10 gms per day (according to Asia-Pacific Guidelines) or > 21 standard drink per week in women (according to EASL guideline).

**Non-invasive tests for diagnosis of hepatic steatosis**

### Imagings for diagnosis of hepatic steatosis

| Table 1 | Histological and ultrasonographic grading of hepatic steatosis |
|---------|---------------------------------------------------------------|
| Grading of hepatic steatosis | Histological findings | Ultrasonographic findings |
| Grade 0 steatosis | Less than 5% of hepatocytes contain fat |  |
| Grade 1 steatosis | 6–33% of hepatocytes contain fat | Hepatic echogenicity is more than the renal cortex. |
| Grade 2 steatosis | 34–66% of hepatocytes contain fat | Liver echogenicity obscures echogenic wall of portal venous branches. |
| Grade 3 steatosis | > 66% of hepatocytes contain fat | Diaphragmatic wall and portal venous walls are not visible due to increased hepatic echogenicity. |

A. Abdominal ultrasonography: Usually, “Hepatic steatosis” is diagnosed incidentally by abdominal ultrasonography (USG) which detect the increased echogenicity of the liver and divides fatty liver into three grades (Table 1) [8]. To identify hepatic steatosis, USG has sensitivity from 60 to 94% and specificity from 84 to 95% [9], and sensitivity is more than 90% when liver biopsy shows > 20% steatosis [10] (Fig. 1). Hepatorenal index of 1.34 or higher has sensitivity of 92% and specificity of 85% for identifying steatosis > 5% [11]. Another semiquantitative score (ultrasonographic fatty liver indicator) which requires the presence of liver/kidney contrast (brighter liver than kidney) among other parameters can detect NAFLD when score ≥ 2 [12]. USG has several advantages (non-invasive test, widely available, low cost, quick diagnosis) and disadvantages (degree of fibrosis cannot be detected, low sensitivity when steatosis is less than 20%, and limited use in obese individuals) for detection of fatty liver.

B. Controlled attenuation parameter: Transient elastography is an ultrasound-based study and also known as vibration-controlled transient elastography or Fibroscan which can measure controlled attenuation parameter (CAP). CAP which ranges from 100 to 400 decibels per meter (dB/m) can detect significant hepatic steatosis, but it is less accurate to distinguish between the different grades of hepatic steatosis [13]. However other studies indicate that CAP score is well correlated with steatosis grades in real-world clinical practice [14–16]. The optimal cut-off values of CAP for estimation of hepatic steatosis grades such as S1, S2, and S3 are ≥ 263 dB/m, ≥ 281 dB/m and ≥ 283 dB/m respectively [13]. Another study also graded hepatic steatosis depending on CAP value into S1 ≥ 238 dB/m, S2 ≥ 260 dB/m, and S3 ≥ 293 dB/m [17]. It does not predict liver-related events, non-hepatocellular carcinoma cancers, and cardiovascular events [18]. CAP showed excellent diagnostic performance for differentiating presence and absence of hepatic steatosis by using a cutoff value of 241 dB/m in children with NAFLD but has limited value in evaluating grades of steatosis, especially in children with high BMI (> 30 kg/m²) [19]. Before recommendation for hepatic steatosis measurement, CAP needs further validation.

C. Computed tomography (CT scan): Decreased attenuation of hepatic parenchyma compared to intrahepatic vessels, spleen, and kidney is detected in NAFLD by both contrast-enhanced and non-contrast CT scan. When hepatic density is higher than spleen, hepatic steatosis can be excluded.
## Non Invasive tests for diagnosis of Hepatic steatosis

| Imagings                        | Scoring Systems                              |
|---------------------------------|----------------------------------------------|
| **Abdominal ultrasonography**   | **NAFLD liver fat score (NLFS)**              |
| 1. USG has sensitivity from 60% to 94% and specificity from 84% to 95%. | 1. NLFS value > -0.640 has a sensitivity of 86% and specificity of 71% to identify hepatic steatosis > 5.56%. |
| 2. Sensitivity is > 90% when liver biopsy shows > 20% steatosis.       | 2. Different stages of NAFLD cannot be distinguished. |
| 3. Hepatorenal index of 1.34 or higher has sensitivity of 92% and specificity of 85% for identifying steatosis ≥ 5%. | 3. Higher NLFS is associated with increased liver disease mortality. |
| 4. Ultrasonographic Fatty Liver Indicator score ≥ 2 indicates NAFLD.      |                                              |

| **Controlled Attenuation Parameter** | **Fatty liver index (FLI)** |
|-------------------------------------|-----------------------------|
| The optimal cut-off value of CAP to estimate hepatic steatosis grades: | 1. Fatty liver index: < 30 rules out fatty liver and value ≥ 60 rules in fatty liver (sensitivity: 86% and specificity: 87%) |
| 1. CAP value ≥238 dB/m : S1 (Grade 1) |                                              |
| 2. CAP value ≥260 dB/m : S2 (Grade 2) |                                              |
| 3. CAP value ≥293 dB/m : S3 (Grade 3) |                                              |

| **Computed tomography scan (CT Scan)** | **Hepatic steatosis Index (HSI)** |
|----------------------------------------|----------------------------------|
| Moderate-to-severe hepatic steatosis can be identified when-- | 1. HSI (value < 30) excludes hepatic steatosis with 93.1% sensitivity or |
| 1. Liver attenuation value <40-42 HU or | 3. HSI (value > 36) detects hepatic steatosis with a specificity of 92.4%. |
| 2. Hepatic-spleenic attenuation ratio is < 0.8. | |

| **Magnetic resonance imaging (MRI)** | **Lipid accumulation product (LAP)** |
|-------------------------------------|--------------------------------------|
| 1. MRI to detect histologically confirmed hepatic steatosis: Sensitivity (76.7 to 90.0%) and Specificity (87.1 to 91%) | 1. Cut-off value of LAP for detection of hepatic steatosis in men is 30.5 (sensitivity: 77%, specificity: 75%). |
| 2. Can detect liver fat as low as 5%-10%. | 2. Cut-off value of LAP for detection of hepatic steatosis in women is 23.0 (sensitivity: 82%, specificity: 79%). |
| 3. Hydrogen-1 MR spectroscopy (H-MRS) is a non-invasive technique which can diagnose and quantify hepatic steatosis into three grades. | |
| 4. Proton density fat fraction (PFF) with MRI: It is an accurate biomarker of hepatic steatosis and can discriminate different grades of hepatic steatosis with a good diagnostic accuracy. | |
| 5. Hepatic phosphorus-31 MRS (31P MRS) shows promise in the differentiation of NAFLD stages. | |

| **Xenon-133 liver scan** | **SteatoTest** |
|--------------------------|----------------|
| 1. It is superior to ultrasound with a sensitivity of 94.3% and specificity of 87.5%. | 1. A cut-off value of 0.30 has 90% sensitivity to detect hepatic steatosis. |
| 2. More accurate to detect mild grade of steatosis. | 2. A cut-off of 0.72 has 90% specificity to diagnose hepatic steatosis |
| 3. It is not expected to distinguish between different subtypes of NAFLD. | |
| 4. It does not provide information of liver morphology. | |

| **NAFL screening score** |
|--------------------------|
| 1. The lower cut-off value with a sensitivity of 92% and negative predictive value of 95% is 0.24 |
| 2. The high cut-off value with 90% specificity and positive predictive value of 84% is 0.44 |

---

*[Fig. 1] Non invasive tests for diagnosis of hepatic steatosis*
Hepatic steatosis can be detected in CT scan of the abdomen when spleen attenuation > liver attenuation or when liver attenuation value < 48 Hounsfield units (HU) [20]. Moderate-to-severe hepatic steatosis can be identified with a specificity of 100% when liver attenuation value is < 40–42 HU and hepatic-spleenic attenuation ratio is < 0.8 [21]. Qualitative evaluation of the liver on a portal venous phase contrast-enhanced CT is highly specific to detect hepatic steatosis, but sensitivity (around 60%) is low. CT scan has several limitations such as limited accuracy to detect mild degree hepatic steatosis, risk of radiation exposure, high cost, and availability. CT scan is commonly used to detect hepatic steatosis for living liver donor candidate [22]. Dual energy CT (DECT) findings are strongly correlated with histopathologic findings in cases of steatosis and can allow rapid, accurate evaluations of hepatic steatosis.

D. **Magnetic resonance** imaging (MRI): MRI is considered as the most definitive imaging study for qualitative and quantitative assessment of hepatic steatosis. The sensitivity and specificity of MRI to detect histologically confirmed hepatic steatosis are 76.7 to 90.0% and 87.1 to 91%, respectively [7, 23]. Frequency-selective MRI, chemical-shift-encoded MRI, MR spectroscopy, and magnetic resonance elastography techniques are usually used to assess hepatic fat content [24]. In MRI, both in-phase (IP) and out-of-phase (OOP) imaging to be adequately assessed to detect fatty liver (FL), and in out-of-phase image FL appears as hyper intense (in T1 image), mildly hyper intense (in T2 image), and signal droop out (signal loss is demonstrated when there is 10–15% fat fraction with maximum signal loss occurring when there is 50% fatty infiltration of the liver). Advantages of MRI-based detection of fatty liver are no radiation exposure; high diagnostic accuracy; can detect fat as low as 5–10%; operator independent; highly responsive to changes in steatosis throughout parenchyma; and not significantly impacted by demographics, histologic activity, or co-existing hepatic conditions. It has the following disadvantages: high cost and taking long time.

Hydrogen-1 MR spectroscopy (1H-MRS) is a non-invasive technique which can diagnose and quantify hepatic steatosis into three grades, and H-MHS thresholds correspond with histopathologic grading of steatosis and may obviate liver biopsy (Table 2) [25]. 1H-MRS allows the direct measurement of the area under the lipid resonance peak. This test result is not modified by the presence of confounding factors such as fibrosis, iron overload, and glycogen. Main drawbacks of H-MHS are high cost, less availability, complex technique requiring patient cooperation, samples only a small portion of the entire liver, and not well validated and still considered a research tool.

Proton density fat fraction (PDFF) in MRI is also used for quantifying hepatic steatosis. PDFF is an accurate marker of hepatic steatosis and allows discriminating with a good diagnostic accuracy between different grades of hepatic steatosis [26]. The accuracy of PDFF measurement using chemical shift-encoded methods is similar to that of MRS. Recently, hepatic phosphorus-31 MRS (31P-MRS) is proposed in different studies as a potential marker to detect distinct biochemical changes in different NAFLD stages. It shows promise in the differentiation of NAFLD stages [27].

E. Xenon–133 liver scan: Xe-133 liver scan is a safe, reliable, non-invasive method with low radiation exposure to detect and quantify hepatic steatosis, and is superior to ultrasound with a sensitivity of 94.3% and specificity of 87.5% [28]. Compared with other imaging investigations, Xe-133 scan is more accurate to detect mild grade of steatosis [28]. One major limitation of Xe-133 scan is that it only detects fat; therefore, it is not expected to distinguish between different subtypes of NAFLD and does not provide information of liver morphology. The usefulness of Xe-133 scan in the diagnosis of NAFLD has not been well studied till now (Fig. 1).

### Table 2: Hydrogen-1 MR spectroscopy grading of fatty liver

| Grading of fatty liver | Hydrogen-1 MR spectroscopy findings |
|------------------------|-------------------------------------|
| Grade 0 steatosis      | Proton density fat fraction threshold of less than 17.0% |
| Grade 1 steatosis      | Proton density fat fraction threshold of 17.0–38.6% |
| Grade 2 or greater steatosis | Proton density fat fraction threshold greater than 38.6% |

Non-invasive scoring systems for diagnosis of hepatic steatosis

There is no single laboratory marker that can be used for the diagnosis of NAFLD. Gamma-glutamyltransferase (GGT) in the serum is frequently elevated in NAFLD patients and associated with increased mortality [29], however does not help in diagnosis of NAFLD. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are not sensitive for diagnosis of NAFLD. Following scoring systems are available to identify NAFLD.

A. **NAFLD liver fat score (NLFS):** The NAFLD liver fat score is estimated by using the presence of the metabolic syndrome, type 2 diabetes, fasting serum insulin level, fasting serum AST, and the AST/ALT
Lipid accumulation product (LAP): It is significantly associated with different stages of NAFLD and cannot be distinguished. This score provides a simple and non-invasive tool to predict NAFLD and liver fat content. Higher NLFS is associated with increased liver disease mortality but not with other mortality outcomes [31].

Fatty liver index (FLI): Fatty liver index is a suitable and simple predictor for hepatic steatosis. FLI is calculated by measuring waist circumference, body mass index, serum triglyceride, and gamma-glutamyl transferase [32]. Score varies from zero to 100. Fatty liver index < 30 rules out fatty liver, but value ≥ 60 rules in fatty liver with a sensitivity and specificity of 86% and 87%, respectively [32]. FLI independently associates with overall, cardiovascular and cancer-related mortality. FLI can serve as a surrogate marker for hepatic steatosis and metabolic syndrome in type 1 diabetes [33].

Hepatic steatosis index (HSI): It is a simple, effective NAFLD screening tool derived by a logistic regression model. It includes gender, history of T2DM, body mass index (BMI), alanine transaminase (ALT), and aspartate transaminase (AST). HSI is calculated by the following formula: 

$$\text{HSI} = 8 \times (\text{ALT}/\text{AST} \text{ ratio}) + \text{BMI} \text{ (addition of +2 if female; +2 if diabetes mellitus)}$$

HSI value < 30 excludes NAFLD with 93.1% sensitivity and value > 36 detects NAFLD with a specificity of 92.4% [23]. It may be utilized for selecting individuals for hepatic USG and for determining the need of lifestyle modifications.

Lipid accumulation product (LAP): It is significantly associated with the presence of liver steatosis and has a high diagnostic accuracy to identify NAFLD in the general population, and diagnostic accuracy is higher in young age group individuals [34, 35]. Following calculation is used to measure LAP:

$$\text{LAP} = [\text{waist circumference (cm)} - 65] \times \text{triglyceride concentration (mmol/L) in men and [waist circumference (cm) - 58] \times \text{triglyceride concentration (mmol/L) in women}$$

Cutoff values of LAP in men and women are 30.5 (sensitivity 77%, specificity 75%) and 23.0 (sensitivity 82%, specificity 79%), respectively [35]. Although this is a very simple and low cost test, it needs further validation before recommendation. Lipid accumulation product can also predict metabolic syndrome in individuals without fatty liver disease [36].

SteatoTest: SteatoTest includes ten components such as serum α2-macroglobulin, apo A1, haptoglobin, total bilirubin, GGT, ALT, body mass index, serum cholesterol, triglycerides, and glucose adjusted for age and gender. It is a simple and non-invasive method to identify liver steatosis and may reduce the need for liver biopsy, particularly in patients with component of metabolic syndrome [37]. A cutoff of 0.30 has 90% sensitivity, and a cutoff of 0.72 has 90% specificity to diagnose hepatic steatosis [37]. It needs further validation before recommendation.

NAFL screening score: It is a model to detect NAFLD with the following six components: age, fasting blood glucose, BMI, triglyceride, ALT/AST, and uric acid. The lower cutoff value with a sensitivity of 92% and negative predictive value of 95% is 0.24, and the high cutoff value with 90% specificity and 84% positive predictive value is 0.44 [38].

**Non-invasive tests for diagnosis of non-alcoholic steatohepatitis (NASH)**

NASH can progress to cirrhosis and its complications such as portal hypertension, liver failure, and hepatocellular carcinoma. Cirrhosis develops in 21 to 28% of NASH patients compared to only 3% of patients with non-alcoholic fatty liver. The gold standard for diagnosis of NASH is liver biopsy. But liver biopsy is an invasive procedure and has several complications, non-invasive tests have been developed for diagnosis of NASH (Fig. 2).

**Serum biomarkers**

A. Serum cytokeratin (CK)-18: It is a marker of hepatocyte apoptosis, most widely investigated for diagnosis of NASH and is the most consistent single parameter for differentiating steatosis from NASH [39]. Cutoff value of CK-18 > 240 U/L has a sensitivity of 76.7% and specificity of 95.0% for diagnosis of NASH [40]. Another study showed that optimal cutoff point of serum CK-18-fragments for definite NASH was 270 U/L with sensitivity and specificity of 64% and 76%, respectively [41].

B. Serum aminotransferases: It is commonly used in clinical practice as a surrogate marker for liver inflammation but has poor predictive value for diagnosis of NASH [5]. Serum alanine aminotransferase (ALT) value > 2 times the upper limit of normal (> 70 U/L) has a sensitivity of 50% and specificity of 61% for NASH detection [42], but ~ 80% of patients with fatty liver have shown ALT levels within normal limits [43]. Aminotransferase levels do not correlate with the degree of hepatic fibrosis. Liver enzymes should not be used for detection of NASH. Further studies are required to
| Serum Biomarkers | Non-invasive scoring systems | Imaging | Proton magnetic resonance (1H-MRS) | Magnetic resonance elastography (MRE) | Breath test |
|-----------------|-----------------------------|---------|----------------------------------|--------------------------------------|------------|
| Serum cytokeatin (CK)-18 | NASH diagnostic index (NDI) | HAIR score | 1. Cut-off value of CK-18 is >240 U/L for diagnosis of NASH (sensitivity: 76.7% and specificity: 95.0%). | 1. Can accurately identify NASH prior to fibrosis. | 1. Analyzing three volatile organic compounds (n-tridecane, 3-methylbutanone, and 1-propanol) in the exhaled breath |
| 1. Cut-off negative predictor for NASH is 29.16 µg/L. | 1. NDI value ≥22 has a specificity of 82% for identifying a diagnosis of simple steatosis | 1. The presence of ≥ 2 parameters predict NASH (sensitivity of 80% and specificity of 89%) | 2. Differentiate NASH from NAFL with a sensitivity of 94% and specificity 73% by using a threshold of 2.74 kPa | 2. Distinguishes patients with NASH from without NASH |
| Serum Adiponectin | Nice model | 1. Cut off value is 0.14 for diagnosis of NASH (84% sensitivity, 86% specificity) | | 3. Negative predictive value of 82% and positive predictive value 81% |
| Fibroblast growth factor 21 (FGF21) | Palekar score | NASH ClinLipMet score | 1. ≥ 3 risk factors distinguishes NASH from steatosis (73.7% sensitivity, 65.7% specificity) | | |
| 1. Its level correlates with severity of steatohepatitis in patients with NASH. | 1. The sensitivity of this scoring system is 75%. | 1. The sensitivity of this scoring system is 75%. | 2. This test is usually used in research because of high cost. | | |
| 2. FGF21 level may help to identify patients who is having highest risk of disease progression. | 2. This test is usually used in research because of high cost. | 2. This test is usually used in research because of high cost. | | | |
| Proprotein convertase subtilisin/kexin type 9 (PCSK9) | NASH predictive index (NPI) | NAFIC score | 1. Predicting the presence of NASH, this index is promising (AUROC of 0.87 to 0.90) | | |
| 1. Circulating PCSK9 increases with hepatic fat accumulation. | 1. This score includes ferritin, fasting insulin, and type IV collagen 7S. | 1. This score includes ferritin, fasting insulin, and type IV collagen 7S. | | | |
| 2. Correlates with the severity of steatosis. | | | | | |
| Plasma pentraxin 3 (PTX3) | Gholam score | | | | |
| 1. Higher serum concentration is seen in patients with more advanced stages of NAFLD. | NASH Score | | | | |
| Malondialdehyde (MDA) | oxNASH score | | | | |
| 1. High serum level is seen in patients with NASH than without NASH | | | | | |
| Tumor Necrosis Factor Alpha (TNF-α) | Interleukin-6 (IL-6) | | | | |
| 1. It is elevated in patients with NASH. | 1. IL-6 is positively correlated with severity of hepatocyte inflammation, stage of fibrosis in patients with NASH. | | | | |
| 2. High level of TNF-α has increased higher adverse hepatic events risk compared to patients with low level of TNF-α | | | | | |
find out cutoff value of liver enzymes to prevent unnecessary diagnostic work-ups and early detection of NASH.

C. Serum adiponectin: Adiponectin is exclusively synthesized by adipose tissue and involves in glucose and lipid metabolism. It is a negative predictor of NASH in fatty liver patients with a cutoff value 29.16 μg/mL [44].

D. Fibroblast growth factor 21 (FGF21): Serum FGF21 level correlates with severity of steatohepatitis in patients with NASH, and its level may help to identify patients who are having highest risk of disease progression. Plasma FGF21 was higher in patients with NASH with mean value of 453 ± 262 pg/mL when compared to patients without NASH [45]. To improve the positive predictive value (PPV) and negative predictive value (NPV) of FGF21, CK-18 is combined with FGF21, which improves the PPV to 82% and NPV to 74% [46].

E. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocytes secrete PCSK9 which inhibits the uptake of low-density lipoproteins by targeting the receptor for degradation and possibly lipogenesis. In a recent study, Paquette et al. described strong association between PCSK9 and liver biomarkers as well as hepatic steatosis [47]. Circulating PCSK9 increases with hepatic fat accumulation and also correlates with the severity of steatosis [48].

F. Plasma pentraxin 3 (PTX3): Higher serum concentration of pentraxin 3 protein is seen in patients with more advanced stages of NAFLD, and higher values are correlated with advanced stages of the hepatic fibrosis. Therefore, serum PTX3 level could be used as a marker to assess severity of hepatic fibrosis [49].

G. Malondialdehyde (MDA): High serum level of malondialdehyde is seen in type 2 diabetes patients with NASH than without NASH [50]. MDA can stimulate hepatic stellate cells and result in fibrosis.

H. Tumor necrosis factor alpha (TNF-α): Tilg et al. described that TNF-α is elevated in serum of those with NASH [51]. Patients with high level of TNF-α have increased burden of NAFLD and higher adverse hepatic event risk compared to patients with low level of TNF-α [51].

I. Interleukin-6 (IL-6): Elevated serum IL-6 is associated with an increased likelihood of exhibiting NAFLD. IL-6 is positively correlated with severity of hepatocyte inflammation, stage of fibrosis in patients with NASH [52]. However, Yoneda et al. in their study did not find any increase in expression of IL-6 in patients with steatohepatitis as compared to patients with simple hepatic steatosis [53].

Non-invasive scoring systems for diagnosis of steatohepatitis (NASH)

A. NASH test: NASH test is a simple and non-invasive scoring system to predict the presence or absence of NASH in patients with non-alcoholic fatty liver disease [54]. It includes 13 components (age, sex, height, weight, serum levels of triglycerides, cholesterol, a2-macroglobulin, apolipoprotein A1, haptoglobin, g-glutamyltransferase, aminotransferases ALT, AST, and total bilirubin) to identify NASH and divide NASH into three categories: NASH (AUROC of 0.79), Borderline NASH (AUROC of 0.69), and No-NASH (AUROC of 0.77–0.83) [55].

B. HAIR score: This score depends on the following parameters: hypertension, alanine aminotransferase [ALT] level, and insulin resistance. The presence of at least two of the three parameters provides the best combination of sensitivity of 80% and specificity of 89% for predicting NASH especially in severely obese individuals [56].

C. NASH diagnostic index (NDI): This index is calculated by serum insulin, glucose, triglycerides, ALT, and waist-to-hip ratio. By using a value ≥ 22, NDI has a specificity of 82% for establishing a diagnosis of simple steatosis, and NDI has a specificity of 86% for diagnosing NASH when value is ≥ 50 [57].

D. NICE model: A simple and non-invasive composite model includes metabolic syndrome (MS), CK-18, and serum ALT level. This model is designed to diagnose NASH in morbidly obese patients. The equation of “Nice model” is: −5.654 + 3.780E−02 × ALT (IU/L) + 2.215E−03 × CK18 fragment levels (IU/L) + 1.825 × (presence of MS = 1) [58]. The best cutoff value is 0.14 for diagnosis of NASH and this value is associated with 84% sensitivity, 86% specificity, 44% positive predictive value, and 98% negative predictive value.

E. Palekar score: It was proposed to distinguish NASH from steatosis. This scoring system includes the following risk factors: age ≥ 50 years, female gender, AST ≥ 45 IU/L, body mass index (BMI) ≥ 30 mg/kg2, AST/ALT ratio ≥ 0.80, and hyaluronic acid ≥ 55 μg/L. The presence of three or more risk factors has 73.7% sensitivity and 65.7% specificity to distinguish NASH from steatosis [59].

F. NAFIC score: This score is used by using ferritin, fasting insulin, and type IV collagen 7S for predicting non-alcoholic steatohepatitis in NAFLD patients [60].

G. NASH ClinLipMet score: This test is used by utilizing serum AST value, fasting insulin value, PNPLA3 genotype, glutamate, isoleucine, glycine,
lysophosphatidylcholine 16:0, and phosphoethanolamine 40:6. The sensitivity of this scoring system is 75% [55]. This test is usually used in research because of high cost.

H. NASH predictive index (NPI): This index is used by using age, female gender, body mass index (BMI), homeostatic model assessment (HOMA) of insulin resistance, and log [aspartate aminotransferase (AST) × ALT]. For predicting the presence of NASH, this index is promising (AUROC of 0.87 to 0.90) but lacks external validation [61].

I. Other scoring systems: Gholam score (AST and diabetes mellitus) [62] and oxNASH (13-hydroxy-octadecadienoic acid/linoleic acid ratio, age, BMI, and AST) score > 72 were 10 times more likely to have NASH compared to those with oxNASH score < 47 [63], and a clinical score by Chunming et al. [64] including ALT, gamma-glutamyl transpeptidase, C-reactive protein, and ApoB/ApoA1 ratio, NASH Score [65] (AST, PNPLA3 genotype and fasting insulin) were studied for identification of NASH.

Breath test for diagnosis of non-alcoholic steatohepatitis
A study showed that analyzing three volatile organic compounds (n-tridecane, 3-methyl-butanonitrile, and 1-propanol) in the exhaled breath were sufficient to distinguish patients with NASH from without NASH with negative and positive predictive values of 82% and 81%, respectively [66].

Imagings for diagnosis of non-alcoholic steatohepatitis
Routine imaging techniques (Ultrasonography, CT, or MRI) are unable to differentiate NASH from simple steatosis.

A. Proton magnetic resonance (1H-MRS): This method is studied in detecting NASH with a sensitivity of 87.4% and specificity of 74.3% [67].

B. Magnetic resonance elastography (MRE): MRE can accurately identify NASH prior to fibrosis and differentiate NASH from NAFL with a sensitivity of 94% and specificity 73% by using a threshold of 2.74 kPa [68]. But it needs further validation.

Non-invasive tests for diagnosis of hepatic fibrosis:
Stages of liver fibrosis are the most important factor for the prognosis of NAFLD and predicting the risk of progression to cirrhosis and its complications. There are several predictive models available to identify hepatic fibrosis (Fig. 3).

Non-invasive scoring systems for diagnosis of hepatic fibrosis
A. AST/platelet ratio index (APRI): This is measured by using the patient’s AST level, upper limit of normal AST value, and platelet count. APRI cutoff of ≥ 0.7 has a sensitivity of 77% and specificity of 72% to detect significant hepatic fibrosis (≥ F2 by Metavir) and a cutoff score of at least 1.0 has a sensitivity of 61 to 76% and specificity of 64 to 72% for detection of severe fibrosis/cirrhosis (F3 to F4 by Metavir) [69]. APRI has a good negative predictive value to exclude advanced fibrosis but does not accurately differentiate intermediate fibrosis from mild or severe fibrosis.

B. FIB-4: It is a simple, accurate, and inexpensive method for assessing liver fibrosis and includes the following components: age, platelet count, AST, and ALT. It is calculated by using [age (years) × AST (U/L)]/[number of platelets (10^9/L) × ALT (U/L) (1/2)] formula. An FIB-4 score > 3.25 has a positive predictive value of 82.1% with a specificity of 98.2% to confirm the existence of a significant fibrosis (F3-F4 by Metavir) [70]. FIB-4 has high negative predictive value (> 90%) for ruling out advanced fibrosis when score is < 1.45.

C. BARD score: This is calculated by using the sum of 3 variables (BMI ≥ 28 = 1 point, AST-to-ALT Ratio ≥ 0.8 = 2 points, the presence of diabetes = 1 point), and score ≥ 2 is associated with advanced fibrosis [71]. Due to its simplicity, it is popular among general practitioners. However due to its low positive predictive value (≤ 42%) it includes many patients without NASH/ fibrosis into high risk group and limits its utility in clinical practice.

D. NAFLD fibrosis score (NFS): A simple scoring system accurately separates NAFLD with and without advanced fibrosis. It includes age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio as variables. By using low cutoff score of -1.455, advanced hepatic fibrosis could be excluded with high negative predictive value of 93%, and by applying the high cutoff score of 0.676, advanced hepatic fibrosis could be diagnosed with high positive predictive value of 90% [72]. Advantages of the NFS are as follows: (1) its ability to provide prognostic information and (2) identify NAFLD patients who are at increased risk for liver-related complications such as ascites and gastroesophageal varices or death.

E. King’s score: The King’s score is a simple index for predicting cirrhosis and calculated by the following formula: age × AST (U/L) × INR/platelet count
| Scoring systems                      | Imaging systems                        |
|-------------------------------------|----------------------------------------|
| **AST/Platelet Ratio Index (APRI)** | **Transient Elastography (Fibroscan)**  |
| 1. Cut-off value is ≥ 0.7 to detect significant hepatic fibrosis (≥ F2 by Metavir) |
| 2. Has an sensitivity of 77% and specificity of 72%   |
| **FIB-4 score**                     | **Acoustic Radiation Force Impulse (ARFI) elastography** |
| 1. Score > 3.25 has a positive predictive value of 82.1% with a specificity of 98.2% to confirm the existence of a significant fibrosis (F3-F4 by Metavir) |
| **BARD score**                      | **Shear wave elastography (SWE)**       |
| 1. Score ≥ 2 is associated with advanced fibrosis |
| 2. Low positive predictive value (42%) limits its utility in clinical practice |
| **NAFLD fibrosis score (NFS)**      | **Magnetic Resonance Elastography (MRE)** |
| 1. By using low cut-off score of -1.455, advanced hepatic fibrosis could be excluded with high negative predictive value of 93% |
| 2. By applying the high cut-off score of 0.676, advanced hepatic fibrosis could be diagnosed with high positive predictive value of 90% |
| **King's score**                    |                                         |
| 1. Score ≥ 16.7 predicts cirrhosis with sensitivity 86%, specificity 80% and a high negative predictive value of 96% |
| **Fibrosis Index score (FI)**       |                                         |
| 1. Sensitivity and positive predictive value of FI score ≥ 3.30 for the prediction of F4 is 70.8% and 81.0% respectively |
| **Enhanced Liver Fibrosis (ELF) panel** |                                         |
| 1. It has 3 cut-off values:         |                                         |
|   (1) value 7.7 for exclusion of fibrosis, |
|   (2) value 9.8 for identification of fibrosis with sensitivity of 69%, specificity of 98% for moderate fibrosis, |
|   (3) value 11.3 to discriminate cirrhosis with 83% sensitivity and specificity of 97% |
| **FibroTest**                       |                                         |
| 1. Cut-off value of 0.30 has 90% negative predictive value for advanced fibrosis with sensitivity of 77% |
| 2. Cut-off value of 0.70 has a 73% positive predictive value for advanced fibrosis with specificity of 98%. |
| **Fibroindex**                      |                                         |
| **Forns Index**                     |                                         |
| **Fibrospect II**                   |                                         |
| 1. Score > 0.42 indicates presence of stage F2 to F4 fibrosis with sensitivity of 80.6% and specificity of 71.4% |

Fig. 3 Non invasive tests for diagnosis of hepatic fibrosis
(10⁹/L). Score of ≥ 16.7 predicts cirrhosis with sensitivity 86%, specificity 80%, and a high negative predictive value of 96% [73]. This score was initially evaluated for diagnosis of cirrhosis in patients with hepatitis C infection.

F. Fibrosis index score (FI): This is a simple index to detect hepatic fibrosis noninvasively and measured by “8 – 0.01 × number of platelets (10⁹/L) – albumin (g/dL)” formula. Sensitivity and positive predictive value of FI score ≥ 3.30 for the prediction of F4 is 70.8% and 81.0%, respectively [74].

G. Cao et al. published a score by measuring CK-18, ALT, platelets, and triglycerides that had significant positive correlation with staging hepatic fibrosis [75].

H. Egy-Score: This score is a useful non-invasive panel of surrogate biomarkers that can accurately predict stages of hepatic fibrosis. Egy-Score was calculated by the following formula: 3.52 + 0.0063 × CA19-9 + 0.0203 × age + 0.4485 × alpha-2-macroglobulin + 0.0303 × bilirubin – 0.0048 × platelet – 0.0462 × albumin [76].

I. Enhanced liver fibrosis (ELF) panel: It includes three variables: hyaluronic acid, tissue inhibitor of metalloproteinase-1, and aminoterminal peptide of procollagen III. It has 3 cutoff values: (1) value 7.7 for exclusion of fibrosis, (2) value 9.8 for identification of fibrosis with sensitivity of 69% and specificity of 98% for moderate fibrosis, and (3) value 11.3 to discriminate cirrhosis with 83% sensitivity and specificity of 97% [77].

J. FibroTest: This is calculated using five biomarkers: haptoglobin, α2-macroglobulin, apolipoprotein A1, total bilirubin, and GGT. Cutoff value of 0.30 has 90% negative predictive value for advanced fibrosis with sensitivity of 77%, and a cutoff value of 0.70 has a 73% positive predictive value for advanced fibrosis with specificity of 98%. False positive result is seen in Gilbert’s syndrome, cholestasis, acute hemolysis, renal insufficiency, on medications that may cause unconjugated hyperbilirubinemia, and acute liver inflammation [78].

K. Fibroindex: This simple scoring system is measured by using the following three biochemical markers: AST, platelet count, and gamma globulin. It has good specificity for mild or significant fibrosis (94% and 97% respectively) but has low sensitivity (40% and 36% respectively) [79]. Due to its low sensitivity, it is not an adequate tool to be used alone for detection of hepatic fibrosis.

L. HepaScore: Age, sex, total bilirubin, GGT, alpha-2-macroglobulin, and hyaluronic acid levels are used to calculate HepaScore. Score ≤ 0.2 has 98% negative predictive value to exclude fibrosis and ≥ 0.8 has a positive predictive value of 62% to predict cirrhosis [80].

M. Forns index: It has the following components: age, gamma-glutamyltransferase (GGT), cholesterol, and platelet count. Score < 4.25 has a negative predictive value of 96% to exclude significant fibrosis and value > 6.9 has positive predictive value of 66% for diagnosis of significant fibrosis [81].

N. Fibrospect II: This test (including hyaluronic acid, tissue inhibitor of a metalloproteinase-1 (TIMP-1), and alpha-2-macroglobulin as variables) can be used to predict stages of hepatic fibrosis (F2 to F4). Score > 0.42 indicates presence of stage F2 to F4 fibrosis with sensitivity of 80.6% and specificity of 71.4% [82].

Imagings for diagnosis of hepatic fibrosis

A. Transient elastography (Fibroscan): This is an easy-to-perform, non-invasive, day care procedure which takes about 5 to 10 min and measures the velocity of 50 MHz shear wave that is emitted by ultrasound transducer probe and transmitted through hepatic tissue. This velocity of share wave in the liver is positively related to liver stiffness, and value ranges from 1.5 to 75 kPa. Fibroscan examines a larger area of liver tissue (1 cm diameter × 5 cm in length) than liver biopsy and provides a more representative assessment of the entire hepatic parenchyma. Two types of probe are available to measure hepatic stiffness: “M” probe is the most commonly used to measure shear wave velocity, and “XL” probe is usually used in obese people to reduce the failure rate. Cutoff value of < 8 kPa has a 94–100% negative predictive value to exclude significant hepatic fibrosis [83], and cutoff values used to identify stages of hepatic fibrosis are as follow: 7.1 kPa for F ≥ 2, 9.5 kPa for F ≥ 3, and 12.5 kPa for F4 [84]. Conditions which increase liver stiffness without fibrosis are acute hepatitis, hepatic congestion (e.g., in heart failure), mass lesions within the liver, and cholestasis. Failure or unreliable to take readings are seen more frequently in the following patients: obesity (BMI > 30–35 kg/m²), older age, and presence of ascites. There are no absolute contraindications for this test, however manufacturer also advises against the use of this device in pregnancy and in patients with a pacemaker and implantable defibrillators. Despite these limitations, Fibroscan is one of the more reliable non-invasive methods to estimate liver fibrosis and is recommended during the management of NAFLD in the current guidelines [5].
B. Acoustic radiation force impulse (ARFI) elastography: ARFI uses a conventional B-mode ultrasonography probe which produces an acoustic pulse. Hepatic stiffness is expressed as shear wave velocity in meter per second (m/s) after calculating the median for 10 successful measures. Using a predictive shear stiffness of 4.24 kPa, it distinguishes low (fibrosis stage 0–2) from high (fibrosis stage 3–4) fibrosis stages with a sensitivity of 90% and a specificity of 90% [85]. The advantages of ARFI are as follows: (1) the acoustic energy pulse is not affected by obesity or ascitic fluid, (2) specific regions of interest can be focused during procedure to measure varying depths in specific areas of the liver, (3) at the same time whole liver can be evaluated by ultrasonography which is not possible with Fibroscan. However, the presence of severe steatosis can affect accuracy of ARFI [86].

C. Shear wave elastography (SWE): By using conventional ultrasonography machine, SWE estimates liver stiffness in the right lobe and positively correlated with liver fibrosis severity and can potentially differentiate intermediate degrees of liver fibrosis in patients with NAFLD. Shear waves produced by a conventional ultrasound beam are directly related to the hepatic stiffness and are reported to be more accurate than transient elastography in assessing significant fibrosis of the liver (LS) (≥ F2) [87]. Hepatic stiffness is measured in the right lobe of the liver, and measurement of LS in the left lobe is inappropriate because it is affected by cardiac pulsation. In healthy population, liver stiffness value ranges in between 4.5 and 5.5 kPa [88]. Food intake increases LS value and results in falsely high fibrosis stages, and usually 180 min after food intake, value comes to the normal range; therefore, it is recommended to measure hepatic stiffness at least 4 h after food intake [89]. By using cut-off values of 7.10 kPa and 9.1 kPa to detect, F ≥ 2 and F ≥ 3 have sensitivity and specificity of 93.8% and 52%, and 93.1% and 80.8% respectively [85]. When 13 kPa and 15.73 kPa are used to detect F4 fibrosis, the sensitivity and specificity are 75.3 and 87.8, and 100% and 82% respectively [90, 91].

D. Magnetic resonance elastography (MRE): It can assess a larger surface area of the liver or the entire liver than US-based modalities and is not limited by ascites and obesity. MRE has a sensitivity of 94% and specificity of 95% to differentiate F0 to F1 from F2 to F4, and 98% sensitivity and 94% specificity in differentiating F0 to F3 from F4 [92]. A cutoff value of > 3.63 kPa has a sensitivity of 86%, specificity of 91%, NPV of 97%, and PPV of 68% to discriminate advanced fibrosis (F3–F4) from stage F0 to F2 fibrosis [93]. Limitations of MRE are as follows: (1) it cannot be applied to individuals with hepatic iron overload due to the interfering signal intensity, (2) high cost of MRE, (3) needs further validations.

Emerging genetic biomarkers for diagnosis of different stages of NAFLD

Several genetic biomarkers were studied to diagnose or identify different stages of NAFLD. However, it needs further research before recommendations on emerging genetic biomarkers.

A. Lipidomic serum tests: These tests distinguish NAFLD from normal liver (NL) and NASH from non-alcoholic fatty liver (NAFL) with high accuracy. The diagnostic performances of the validated tests for discrimination between NAFLD and NL show sensitivity and specificity of 0.94 and 0.57, respectively and sensitivity of 0.70 and specificity of 0.81, respectively for the discrimination between NASH and NAFL [94].

B. Proteomic analysis: This analysis can be used to differentiate simple steatosis from NASH with significant fibrosis (F3/F4 group), and the NASH with significant fibrosis (F3/F4 group) and without significant fibrosis [95]. Complement component C7 was three-fold higher in the NASH group with significant/advanced fibrosis (F2–F4) compared with the early NASH (F0–F1). Complement component C7 and Fibulin-1 are positively correlated with liver stiffness, whereas complement component C8 γ chain is negatively correlated. High levels of complement C7 are associated with NASH with significant/advanced fibrosis [96].

C. Gut microbiome-based metagenomic signature: Gut microbiome compositions using whole-genome shotgun sequencing of DNA extracted from stool can be used to identify advanced hepatic fibrosis in NAFLD patients. The gut microbiomes in NAFLD are dominated by members of Bacteroidetes and Firmicutes followed by Actinobacteria and Proteobacteria in much lower amount. Proteobacteria phylum has a statistically significant increase in amount (while the Firmicutes phylum decrease) as the disease progresses from mild/moderate NAFLD to advanced fibrosis [97].

Management of NAFLD (Fig. 4)

NAFLD patients without NASH and hepatic fibrosis are treated by lifestyle changes which include diet modification and moderate physical exercise along with treatment of underlying causes. Pharmacotherapy is available in presence of NASH and fibrosis (≥ 2). NAFLD patients with an advanced liver fibrosis (ELF
test > 10.51) a indication for pharmacotherapy in the NICE guideline [98]. Patients with NASH should be the main target of treatment due to higher risk of mortality related to the disease. A weight loss of at least 7% is required for histological improvement in obese NASH patients.

A. Lifestyle modification: It is an effective therapy to downgrade hepatic injury in NAFLD patients [99].

Diet modification: Energy restriction with a low calorie, low fat, and low carbohydrate or high-protein
Mediterranean diet is advised in NAFLD patients. 500–1000 kcal deficit diet per day to induce a weight loss of 500–1000 g/week is usually recommended (according to EASL, Asia-Pacific and AASLD guidelines). According to the Italian Association for the Study of the Liver (IASL), amount of fat and carbohydrate should be < 30% and < 50% of total calories respectively.

Coffee drinking is protective in NAFLD by reducing histological severity and liver-related outcomes and inversely related to the steatohepatitis severity [100]. Therefore daily coffee consumption should be encouraged in NAFLD patients. Coffee intake ≥ 2 cups/day improves NAFLD and reduces liver-related morbidities [101]. Caffeine inhibits proliferation of hepatic stellate cell, thus exerting an anti-fibrogenic effect via adenosine receptor blockade [102].

Fructose-containing beverages and foods should be avoided because it appears as one major factor for initiation of hepatic steatosis and also its progression to NASH and more severe stages of the liver fibrosis [103, 104]. Alcohol intake should be < 30 g/day for men and < 20 g/day for women but better to avoid alcohol consumption of any type or amount in individuals with NAFLD [105].

Omega-3 fatty acid supplementation reduces hepatic steatosis and improves serum gamma-glutamyltransferase, triglyceride, and high-density lipoprotein in patients with NAFLD; therefore, omega-3 fatty acid supplementation may be a new treatment option for NAFLD [106, 107]. But according to AASLD guideline (2018), omega-3 fatty acid should not be used as a specific treatment of NAFLD or NASH, but it can be used to treat hypertriglyceridemia in NAFLD patients [5].

Physical exercise: Both moderate and vigorous aerobic exercise (e.g., brisk walking, stationary cycling) and resistance training (150–200 min/week in 3–5 sessions) is effective to reduce hepatic steatosis by reducing weight, and choice of exercise should be based on patients’ preference [108]. In general, 5 to 10% reduction in body weight in obese or overweight people over 6 to 12 months has been advocated through diet modification and physical exercise. At least 3–5% of body weight loss is necessary to improve hepatic steatosis, but > 7% weight loss is required for histological improvement in NASH and fibrosis [5].

Therefore, the first line intervention in the management of NAFLD is lifestyle modification which includes (1) at least 7–10% weight loss by a combination of low-calorie diet with discource of high fructose and saturated fat in foods. Diet with omega-3 fatty acid supplement may be advised, and (2) moderate to vigorous physical activity.

B. Pharmacotherapy: Only few drugs are recommended in the treatment of biopsy-proven NASH and fibrosis stage ≥ 2 or Fibroscan value > 10.51.

Pioglitazone: It is a peroxisome proliferator-activated receptor (PPAR) gamma agonist which improves histological features in biopsy-proven NASH patients with and without type 2 diabetes mellitus. Fifteen to thirty milligrams daily dose of Pioglitazone is recommended in the above indication. The optimal duration of therapy is unknown, but according to EASL guideline [107], treatment should be stopped if there is no reduction in aminotransferases after 6 months of therapy, and in patients with normal ALT at baseline, no recommendations can be made. Bone loss in women and weight gain are common side effect associated with use of Pioglitazone. Bladder cancer has been a concern during use of Pioglitazone, but another study found that there is no statistically significant association between use of Pioglitazone and risk of bladder cancer [109].

Vitamin E: It is superior to placebo for the treatment of NASH in adults without diabetes, and compared with placebo, vitamin E use is associated with significantly higher rate of improvement in non-alcoholic steatohepatitis (43% vs. 19%). It reduces hepatic steatosis and lobular inflammation, but no improvement in hepatic fibrosis scores [110]. According to AASLD and NICE guidelines, vitamin E may be considered at a dose of 800 IU/day in nondiabetic adults with biopsy-proven NASH [5]. But according to Asia-Pacific guideline, vitamin E therapy is not beneficial for NASH management [111].

Saroglitazar: Saroglitazar (dual PPAR α/γ agonist) at a dose of 4 mg improves ALT value and fatty liver (evaluated by transient elastography) in patients with NAFLD and diabetic dyslipidemia [112]. Saroglitazar can be a potential therapeutic option for the management of metabolic syndrome associated NAFLD and NASH [113]. Another study from India with 12 months follow-up showed that Saroglitazar is safe and effective in management of NAFLD patients and is a potential option in the future [114]. But it needs further exploration before recommendation.

Liraglutide: It is a glucagon-like peptide-1 (GLP-1) analog which is safe, well tolerated, and associated with histological improvement of non-alcoholic steatohepatitis with 1.8 mg subcutaneous injections daily [115]. Most common side effects are diarrhea, constipation, and loss of appetite. However, it needs large studies for further evaluation for recommendation for the treatment of NAFLD.

Ursodeoxycholic acid (UDCA): Histological activities of NASH are not improved by using UDCA (13–15 mg/kg/day) alone, but improvements are seen when...
combination of vitamin E and UDCA is given [116]. High-dose UDCA (23–28 mg/kg/day) also fails to improve the overall histology in patients with NASH [117]. According to NICE, EASL, Asia-pacific, and AASLD guidelines, UDCA is not recommended for treatment of NAFLD, NASH, or hepatic fibrosis however few recent articles showed positive results [118, 119]. Parikh et al. in their study indicated that UDCA is an effective and safe alternative to vitamin E in non-diabetic–non-cirrhotic Indian NAFLD patients [118]. Another systemic review recommended UDCA as a frontline therapeutic option for NASH, thereby preventing its progression to cirrhosis and liver cancer [119].

Obeticholic acid: This synthetic farnesoid X receptor agonist at a dose of 25 mg daily is associated with histological improvement of NASH [120, 121]. Obeticholic acid might become the first approved pharmacotherapy for NASH fibrosis after result of recent multicentre, randomized, placebo-controlled phase 3 trial done by Younossi et al. [122]. For long-term safety and tolerability, it requires further studies, as obeticholic acid can increase low density lipoprotein level and pruritus is also extremely common with high dose of obeticholic acid.

Statin and n-3 polyunsaturated fatty acids: There are no data to support their use specifically for NASH.

SGLT-2 inhibitors: These drugs improve the serum liver enzymes value and reduce hepatic steatosis and fibrosis in type 2 diabetes patients with NAFLD [123]. Therefore use of SGLT2-inhibitors in type 2 diabetes patients with NAFLD is promising. Further researches are required to progress in this evolving field.

Others emerging drugs for management of NAFLD:

Elafibranor: It is a peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ agonist and improves insulin sensitivity, glucose homeostasis, and lipid metabolism, and reduces inflammation. Ratziu et al. in their study showed that elafibranor (120 mg/day for 1 year) resolved NASH without fibrosis worsening [124]. It has an effect on the resolution on NASH and impromves two key drivers of NASH progression—insulin resistance and serum lipid normalization [125]. It induces nuclear factor-κB results in inhibition of inflammatory genes and decreases the expression of acute-phase response genes [126]. It causes reversible elevation of serum creatinine level; therefore, its use is potentially limiting in patients with concurrent renal disease. Common side effects are congestive heart failure, peripheral edema, bone fractures, and weight gain.

Lanifibranor (IVA337): It is a pan-peroxisome proliferator-activated receptor (PPAR) agonist with moderate and well-balanced activity on the three PPAR isoforms (α, γ, δ). It inhibits proliferation and activation of hepatic stellate cells which are the key cells driving liver fibrogenesis in NASH. It improves liver histology by decreasing liver steatosis, inflammation, and ballooning. Wettstein et al. in their study indicated that lanifibranor has therapeutic potential in the treatment of NASH [127].

Solithromycin: Solithromycin is a highly potent macrolide antibiotic. A clinical trial is going on (NCT02510599) which showed that there is reduction of NAFLD activity score and ALT level after 90 days treatment with Solithromycin in patients with NASH by targeting intestinal microbiomes and metabolic endotoxemia.

Cenicriviroc: Cenicriviroc is a CCR (C—C chemokine receptor) 2 and CCR5 dual antagonist which is playing an important role in macrophage recruitment and polarization in NASH pathogenesis. One phase 2 trial (2018) showed that there was improvement in fibrosis and no worsening of steatohepatitis compared with placebo [128]. Therefore, the drug is now in phase 3.

Selonsertib: It is an apoptosis signal-regulating kinase 1 (ASK1, involved in response to various stresses) inhibitor. Loomba et al. in their phase 2 trial described that selonsertib may reduce liver fibrosis in patients with non-alcoholic steatohepatitis and stage 2–3 fibrosis [129]. Now this drug is in phase 3 trial.

Emricasan: It is an oral pan-caspase inhibitor. Lipotoxicity leading to excessive caspase-mediated apoptosis and inflammation is responsible of liver damage in NAFLD. Shiffman et al. in their study showed that emricasan (25 mg twice daily) decreases ALT and biomarkers in NAFLD patients after 28 days of treatment [130].

C. Management of underlying diseases: Along with above treatment, underlying causes of NAFLD should be treated adequately like management of each component of metabolic syndrome if present.

Conclusion

Though liver biopsy is the gold standard test to detect NAFLD and to identify different stages of hepatic steatosis and fibrosis, multiple non-invasive tests are also available nowadays. Few of them are FDA approved and others’ diagnostic tests need further evaluation before recommendation in clinical practice. The NAFLD fibrosis score, transient elastography are recommended to assess hepatic fibrosis and disease activity [5] however for diagnosis of NASH, liver biopsy is required due to lack of...
availability of serum cytokeratine 19 fragments test in clinical practice. Further studies are required to find out cut-off values and role of non-invasive markers and tests for NAFLD before giving approval. Liver biopsy should be considered in the following conditions: (1) when a competing etiology of chronic liver disease cannot be excluded just by non-invasive methods, (2) suspect of NAFLD-related advanced liver disease. Treatment of NAFLD can be divided into lifestyle modification (including diet restriction, low calorie diet intake, physical exercise leading to weight loss), pharmacotherapy (restricted to NAFLD patients with NASH and fibrosis), and management of underlying causes of NAFLD. Early diagnosis and proper management are required to avoid longterm complications of NAFLD.

Abbreviations
NAFLD: Non-alcoholic fatty liver disease; LFT: Liver function test;
USG: Ultrasonography; CAP: Controlled attenuation parameter; BMI: Body mass index; CT: Computed tomography; MR: Magnetic resonance imaging; 1H-MRS: Hydrogen-1 MR spectroscopy; PDDF: Proton density fat fraction; 31P-MRS: Hepatic phosphorus-31 MRS; GGT: Gamma-glutamyltransferase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NIFLS: NAFLD liver fat score; FIB-4: Fatty liver index; HSI: Hepatic steatosis index; TZDM: Type 2 diabetes mellitus; LAP: Lipid accumulation product; NAFL: Non-alcoholic fatty liver; NASH: Non-alcoholic steatohepatitis; CK: Serum cytokeratine; FGF21: Fibroblast growth factor 21; PPV: Positive predictive value; NPV: Negative predictive value; NDI: NASH diagnostic index; MS: Metabolic syndrome; NPI: NASH predictive index; HOMA: Homeostatic model assessment; 1H-MRS: Proton magnetic resonance; MRE: Magnetic resonance elastography; APRI: Aspartate aminotransferase/platelet ratio index; NIFLS: NAFLD fibrosis score; FI: Fatty liver index; ELF: Enhanced liver fibrosis; ARFI: Acoustic radiation force impulse; SWE: Shear wave elastography; LS: Liver stiffness; MRE: Magnetic resonance elastography; UDCA: Ursodeoxycholic acid; SGLT-2 inhibitor: Sodium-glucose cotransporter-2 inhibitor; FDA: Food and Drug Administration

Acknowledgements
Not applicable.

Author’s contributions
The author contributed in the interpretation of the study data, manuscript writing, and revising. The author read and approved the final manuscript.

Funding
Nil

Availability of data and materials
Data materials are available under reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The author declares that he has no competing interests.

Received: 16 March 2020 Accepted: 1 July 2020
Published online: 28 July 2020

References
1. Armstrong MJ, Houllihan DD, Bentham L et al (2012) Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56:234–240
2. Farrell GC, Wong VW, Chitturi S (2013) NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 10:307–318
3. Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84
4. Singh SP, Nayak S, Swain M et al (2004) Prevalence of non-alcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Indian J Gastroenterol. 25:76–79
5. Chalasani N, Younossi Z, Nare J et al (2018 Jan) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 67:328–357
6. Matteoni CA, Younossi ZM, Gramlich T et al (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419
7. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3–16
8. Van Wener JR, Marman HA, Nederveen AJ et al (2010) Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 256:159–168
9. Joseph AE, Savemythuut SH, Al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43:26-31.
10. Dasarathy S, Dasarathy J, Khiyami A et al (2009) Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51:1061–1067
11. Shiralkar K, Johnson S, Bluth EL, Marshall RH, Donnelles A, Gulotta PM (2015) Improved method for calculating hepatic steatosis using the hepatorenal index. J Ultrasound Med. 34:1051–1059
12. Ballestri S, Lonardo A, Romagnoli D et al (2012) Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 32:1242–1252
13. Chan WK, Nick Mustapha NR, Mahadeva S (2014) Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 29:1470–1476
14. Ahn JM, Paik YH, Min SY et al (2016) Relationship between controlled attenuation parameter and hepatic steatosis as assessed by ultrasound in alcoholic or nonalcoholic fatty liver disease. Gut Liver 10:295–302
15. Yen YH, Chen JF, Wu CK et al (2017) The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc. 116:852–861
16. Machado MV (2017) Controlled attenuation parameter as a noninvasive method to detect and quantify hepatic steatosis in chronic liver disease: what is the clinical relevance? GE Port J Gastroenterol. 24:157–160
17. Sasso M, Beaundrand M, Ledinofel V et al (2010) Controlled attenuation parameter (CAP): a novel VCTE (TM) guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 37:1051–1059
18. Liu K, Wong VW, Lau K et al (2017) Prognostic value of controlled attenuation parameter by transient elastography. Am J Gastroenterol 112: 1812–1823
19. Shin J, Kim MJ, Shin HJ et al (2019) Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRR-DFF as the gold standard. BMC Pediatr 19:112
20. Valls C, lannaccone R, Alba E et al (2006) Fat in the liver: diagnosis and characterization. Eur Radiol. 16(10):2292e308
21. Kari KI, Moshiri M, Cuevas C et al (2012) Imaging patterns of hepatic steatosis on multidetector CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 256:159–168
22. Lee SW, Park SH, Kim KW et al (2007) Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 244:479–485
23. Lee SS, Park SH, Kim H et al (2010) Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52:579–585
24. BLEY TA, WEIBEN O, FRAENZICH EJ et al (2010) Fat and water magnetic resonance imaging. J Magn Reson Imaging. 31:14–18
25. Georgoff P, Thom Asson D, Louie A et al (2012) Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol. 192–7
26. Paparo F, Cenderello G, Revelli M et al (2015) Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. Biomed Res Int. 2015:758164
27. Sevastianova K, Hakkarainen A, Kotronen A et al (2016) Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0T 31P MRI spectroscopy with proton decoupling. Radiology, 256(2):466–473
28. Al-Busafi SA, Ghali P, Wong P et al (2012) The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease. Can J Gastroenterol 26:155–159
29. Ruhl CE, Everhart JE (2009) Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136:477–485
30. Kotronen A, Pelkonen M, Hakkarainen A et al (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137:865–872
31. Unalp-Arida A, Ruhl CE (2018) Liver fat scores predict liver disease mortality in the United States population. Aliment Pharmacol Ther. 48(9):1003–1016
32. Bedogni G, Bellentanti S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6:33
33. Sviklā J, Olmane E, Dźwére Z et al (2018) Fatty Liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol 33:270–276
34. Bedogni G, Kahn HS, Bellentani S et al (2010) A simple index of lipid over accumulation as a good marker of liver steatosis. BMC Gastroenterol 10:98
35. Dai H, Wang W, Chen R et al (2017) Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond) 14:49
36. Cheng YL, Wang YJ, Lan KH et al (2017) Fatty liver index and lipid accumulation product can predict metabolic syndrome in subjects with fatty liver disease. Gastroenterol Res Pract. 2017:9279836
37. Poynard T, Raztzi V, Vaneau S et al (2005) The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 410
38. Zhou YJ, Zhou YF, Zheng JN et al (2017) NAFL screening score: a basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. Clin Chim Acta 475:44–50
39. Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease: A critical appraisal. J Hepatol. 58:1007–1019
40. Maher MM, Ibrahim WA, Saleh SA et al (2014) Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egypt J med Genet 16:41–46
41. Aida Y, Abe H, Tomita Y et al (2014) Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med 7:191–196
42. Vlomma S, Jensen D, Hart J et al (2013) Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in nonalcoholic fatty liver disease (NASH). Liver Int 33:1398–1405
43. Mofrad P, Contos MJ, Haque M et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37:1286–1292
44. Bechmann LP, Kocabayoglu P, Sovaa JP et al (2013) Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in susceptible obese patients with nonalcoholic steatohepatitis. Hepatology, 57:1394–1406
45. Barb D, Bril F, Kalvalapalli S et al (2019) Plasma fibroblast growth factor 21 levels and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 46:53
46. Casonic F, Sampelean D, Buzoiaan AD et al (2016) Serum levels of oxidative stress markers in patients with type 2 diabetes mellitus and non-alcoholic steatohepatitis. Rom J Intern Med. 54(4):228–236
47. Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 14(1):32–42
48. Ruscica M, Ferri N, Macchi C et al (2016) Liver fat accumulation is associated with non-alcoholic steatohepatitis. Gastroenterology, 150(3):573–582
49. Poynard T, Raztzi V, Chafotte F et al (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcohol steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34
50. Zhou Y, Orešič M, Leivonen M et al (2016) Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol 14:1463–1472
51. Mauss S, Berg T, Rockstroh J et al (2018) Hepatology – a clinical textbook, 3rd edn, Germany
52. Younossi ZM, Otgonsuren M, Hunt S et al (2013) Development and validation of Nash diagnostic index as a non-invasive model for diagnosing non-alcoholic hepatosteatosis (Nash). J Hepatol 58:5409–5566
53. Randi E, Iannelli A, Patsouras S et al (2010) A new composite model including metabolic syndrome, adiponectin, adiponectin and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 32:1315–1322
54. Palekar NA, Naus R, Larson SP et al (2006) Clinical model for distinguishing non-alcoholic steatohepatitis from simple steatosis in patients with non-alcoholic fatty liver disease. Liver Int. 26:151–156
55. Sumida Y, Yoneda M, Higoey H et al (2011) A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46:257–268
56. Zien CO, Edmison JM, Schluchter M et al. A NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease [abstract]. Hepatology, 2007; 46:747A.
57. Ghram PM, Flansaam L, Machan JT et al (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102:399–408
58. Alkhouli N, Belk M, Yerian L et al (2014) OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Digestive diseases and sciences. 59:1617–1624
59. Chunming L, Jianhui S, Hongguang Z et al (2015) The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with non-alcoholic fatty liver disease using routine parameters. Turk J Gastroenterol 26:408–416
60. Hyyalo J, Mannitto VT, Zhou Y et al (2014) A population based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60:839–846
61. Verdann FJ, Dallinga JW, Driessen A et al (2013) Nonalcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. Journal of Hepatology. 58:543–548
62. Kim TH, Jeong CW, Jun HY et al (2019) Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. Scientific Reports 9:15002
63. Chen J, Talwalkar JA, Yin M et al (2011) Early detection of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease by using MR elastography. Radiology. 259:749–756
64. Lin ZH, Xin YN, Dong QI et al (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 53:726–736
65. Vallet-Richard A, Mallet V, Nalpas B et al (2007) FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 46:32–36
66. Altrock WM, Arnold HL et al (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57:1441–1447
67. Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45:846–854
68. Cross TJ, Razi P, Berry PA et al (2009) King’s score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 21:730–738
69. Ohsio T, Sakaguchi K, Fujisawa A et al (2006) Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 60:77–84
70. Cao W, Zhao C, Shen C et al (2013) Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One. 8:182602
123. Raj H, Durgia H, Palui R et al (2019) SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes 10:114–132

124. Ratziu V, Harrison SA, Francque S et al (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 150(5):1147–1159

125. Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL (2020) Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 29(2):117–123

126. Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 62(3):720–733

127. Wettstein G, Luccarini JM, Poekes L et al (2017) The new-generation pan-peroxisome proliferator-activated receptor agonist NA337 protects the liver from metabolic disorders and fibrosis. Hepatol Commun. 1(6):524–537

128. Friedman SL, Ratziu V, Harrison SA et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 67(5):1754–1767

129. Loomba R, Lawitz E, Mantry PS et al (2018) The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 67(2):549–559

130. Shiffman M, Freilich B, Vuppalanchi R et al (2019) Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 49(1):64–73

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.